Induction chemotherapy in the management of head and neck cancer

Journal of Surgical Oncology

Volumn 101, Issue 4, 2010, Pages 292-298

  Fury, Matthew G ^a,b   Shah, Jatin P ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Head and neck cancer; Induction chemotherapy; Squamous cell carcinoma

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EVEROLIMUS; FLUOROURACIL; PACLITAXEL; TAXANE DERIVATIVE;

ADD ON THERAPY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; LARYNX CANCER; LARYNX CARCINOMA; MEDICAL LITERATURE; MOUTH CANCER; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; ORGAN PRESERVATION; OROPHARYNX CANCER; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; RASH; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BRIDGED COMPOUNDS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; HEAD AND NECK NEOPLASMS; HUMANS; NEOADJUVANT THERAPY; PATIENT SELECTION; TAXOIDS;

EID: 77749240368     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21438     Document Type: Review

References (60)

1. Jemal A, Siegel R, Ward E, et al.: Cancer Statistics 2009. CA Cancer J Clin 2009;59:225-249.
2. Hashibe M, Brennan P, Benhamou S, et al.: Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and risk of head and neck cancer: Pooled analysis of Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007;99: 777-789.
3. Gillison ML, D'Souza G, Westra W, et al.: Distinct risk factor profiles for human papillomavirus type 16-positive and human papilloma virus type 16-negative head and neck cancers. J Natl Cancer Inst 2008;100:407-420.
4. Shah JP, Patel SG: Head and neck surgery and oncology, 3rd edition. New York: Mosby Publishers; 2003.
5. Posner M, Vermorken JB: Induction therapy in the modern era of combined modality therapy for locally advanced head and neck cancer. Semin Oncol 2008;35:221-228.
6. Wittes R, Heller K, Randolph V, et al.: cis-Dichlorodiam-mineplatimum(II) -based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep 1979;63: 1533-1538.
7. Program HaNC: Adjuvant chemotherapy for advanced head and neck squamous cell carcinoma: Final report of Head and Neck Contracts Program. Cancer 1987;60:301-311.
8. Weaver A, Flemming S, Kish J, et al.: Cis-platinum and 5-fluorouracil as induction chemotherapy for advanced head and neck cancer. Am J Surg 1982;144:445-448.
9. Weaver A, Fleming S, Ensley J, et al.: Superior clinical response and survival rates with initial bolus of cisplatin and 120 hr infusion of 5-fluorouracil before definitive therapy for locally advanced head and neck cancer. Am J Surg 1984;148:525-529.
10. Paccagnella A, Orlando A, Marchiori C, et al.: Phase III Trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-272.
11. Zorat PL, Paccagnella A, Cavaniglia G, et al.: Randomized phase III trial of neoadjuvant chemotherapy in head and neck cancer: 10 year follow up. J Natl Cancer Inst 2004;96:1714-1717.
12. Domenge C, Hill C, Lefebvre JL, et al.: Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. Br J Cancer 2000;83:1594-1598.
13. Licitra L, Grandi C, Guzzo M, et al.: Primary chemotherapy in resectable oral cavity cancer: A randomized clinical trial. J Clin Oncol 2002;21:327-333.
14. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-1690.
15. Lefebvre J-L, Chevalier D, Luboindski B, et al.: Larynx preservation in pyriform sinus cancer: Preliminary results of a European Organization for Research and Treatment of Cancer Phase III Trial. J Natl Cancer Inst 1996;88:890-899.
16. Adelstein DJ, Li Y, Adams GL, et al.: An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003;21: 92-98.
17. Denis F, Garaud P, Bardet E, et al.: Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced stage oropharynx carcinoma. J Clin Oncol 2004;22:69-76.
18. Forastiere AA, Goepfert H, Maor M, et al.: Concurrent chemotherapy and radiotherapy for organ preservation in advanced larynx cancer. N Engl J Med 2003;349:2091-2098.
19. Pignon J, Bourhis J, Domenge D, et al.: Chemotherapy added to locoregional treatment for head and neck squamous cell carcinoma: Three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000;355:949-955.
20. Forastiere A, Shank D, Neuberg D, et al.: Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group Trial (PA390). Cancer 1998;82:2270-2274.
21. Dreyfuss AI, Clark JR, Norris CM, et al.: Docetaxel: An active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 1996;14:1672-1678.
22. Posner MR, Glisson B, Frenette G, et al.: Multicenter phase I-II trial of docetaxel, cisplatin, and fluorouracil induction chemotherapy for patients with locally advanced squamous cell cancer of the head and neck. J Clin Oncol 2001;19:1096-1104.
23. Schrijvers D, Van Herpen C, Kerger J, et al.: Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: A phase I-II feasibility study. Ann Oncol 2004;15:638-645.
24. Hitt R, Paz-Ares L, Brandariz A, et al.: Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: Long term results of a phase II trial. Ann Oncol 2002;13:1665-1673.
25. Vermorken JB, Remenar E, Van Herpen C, et al.: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-1704.
26. Posner M, Hershok DM, Blajman CR, et al.: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-1715.
27. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al.: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-8645.
28. Paccagnella A, Buffoli A, Koussis H, et al.: Concomitant chemoradiotherapy vs neoadjuvant chemotherapy (CT/RT) with docetaxel/cisplatin/ 5-fluorouracil (TPF) followed by CT/RT in locally advanced head and neck cancer. Final results of a phase II randomized study. J Clin Oncol 2008;26: Abstr 6000.
29. Hitt R, Grau JJ, Lopez-Pousa A, et al.: Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU followed by chemoradiotherapy (CRT) versus CRTalone as first line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2009;27: Abstr 6009.
30. Ensley JF, Jacos JR, Weaver A, et al.: Correlation between response to cisplatinum-combination therapy and subsequent radiotherapy in previously untreated patients with advanced squamous cell cancers of the head and neck. Cancer 1984;54: 811-814.
31. Urba S, Wolf G, Eisbruch A, et al.: Single-cycle induction chemotherapy selects patients with advanced laryngeal cancer for combined chemoradiation: A new treatment paradigm. J Clin Oncol 2006;24:593-598.
32. Worden F, Moyer J, Lee JS, et al.: Chemoselection as a strategy for organ preservation in patients with T4 laryngeal squamous cell carcinoma with cartilage invasion. Laryngosope 2009;119:1510-1517.
33. Haddad R, Colevas AD, Tishler R, et al.: Docetaxel, cisplatin, and 5-fluorouracil-based induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck: The Dana Farber Cancer Institute experience. Cancer 2003;97: 412-418.
34. Adelstein DJ, Moon J, Hanna E, et al.: Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/ concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II trial (S0216). Head Neck 2009; June 25 [Epub ahead of print].
35. Fountzilas G, Ciuleanu E, Dafni U, et al.: Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer. Med Oncol 2004;21:95-107.
36. Bonner JA, Harari PM, Giralt J, et al.: Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.
37. van Kuilenburg ABP: Screening for dihydropyrimidine dehydrogenase deficiency: To do or not to do, that's the question. Cancer Invest 2006;24:215-217.
38. Cmelak AJ, Li S, Golwasser MA, et al.: Phase II trial of chemoradiation for organ preservation in resectable stage III or IV squamous cell carcinomas of the larynx or oropharynx: Results of Eastern Cooperative Oncology Group Study E2399. J Clin Oncol 2007;25:3971-3977.
39. Salama JK, Stenson KM, Kistner EO, et al.: Induction chemotherapy and concurrent chemoradiotherapy for locoregionally advanced head and neck cancer: A multi-institutional phase II trial investigating three radiotherapy dose levels. Ann Oncol 2008;19:1787-1794.
40. Belani CP, Barstis J, Perry MC, et al.: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933-2939.
41. Salama JK, Haddad RI, Kies MS, et al.: Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;75:725-733.
42. Fakhry C, Gillison ML: Clinical implications of human papillomaviruses in head and neck cancers. J Clin Oncol 2006;24:2606-2611.
43. Gillison ML, Koch WM, Capone RB, et al.: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-720.
44. Weinberger PM, Yu Z, Haffty BG, et al.: Molecular classification identifies a subset of human pappillomavirus-associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 2006;24: 736-747.
45. Fakhry C, Westra WH, Li S, et al.: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008;100:261-269.
46. Laurie SA, Licitra L: Systemic therapy in the palliative managment of advanced salivary gland cancers. J Clin Oncol 2006;24: 2673-2678.
47. Oh JL, Vokes EE, Kies MS, et al.: Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced nasopharyngeal cancer. Ann Oncol 2003;14:564-569.
48. Hui EP, Ma BB, Leung SF, et al.: Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma. J Clin Oncol 2009;27:242-249.
49. Bossi P, Parolini D, Bergamini C, et al.: TPF induction chemotherapy (CT) followed by concomitant cisplatin/radiotherapy (cCTRT) in locally advanced nasopharyngeal cancer (LANPC). J Clin Oncol 2009;27: Abstr 6046.
50. Loy AH, Reibel JF, Read PW, et al.: Esthesioneuroblastoma: Continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg 2006;132:134-138.
51. Dulguerov P, Allal AS, Calcaterra esthesioneuroblastoma: A meta-analysis and review. Lancet Oncol 2001;2:683-690.
52. Vermorken JB, Mesia R, Rivera F, et al.: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116-1127.
53. Tishler RB, Posner MR, Wirth LJ, et al.: Cetuximab added to docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy (C-TPF) in patients with newly diagnosed locally advanced head and neck cancer: A phase I study. J Clin Oncol 2008;26: Abstr 6001.
54. Fury MG, Pfister D, Sherman E: RAD001 (everolimus) + docetaxel + cisplatin as induction chemotherapy in patients with local-regional advanced head and neck squamous cell carcinoma (HNSCC). www.clinicaltrials.gov: NCT00935961.
55. Molinolo AA, Hewitt SM, Amornphimoltham P, et al.: Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin Cancer Res 2007;13:4964-4973.
56. Beuvink I, Boulay A, Fumagalli S, et al.: The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damage induced apoptosis though inhibition of p21 translation. Cell 2005;120: 747-759.
57. Aissat N, Le Tourneau C, Ghoul A, et al.: Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines. Cancer Chemother Pharmacol 2008;62:305-313.
58. Fury MG, Sherman E, Stambuk H, et al.: Phase I study of everolimus (E; RAD001) + low dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol 2009;27: Abstr e14527.
59. Ross RW, Manola J, Oh WK, et al.: Phase I trial of RAD001 and docetaxel in castration resistant prostate cancer with FDG-PET assessment of RAD001 activity. J Clin Oncol 2008;26: Abstr 5069.
60. Punt CJA, Boni J, Bruntsch U, et al.: Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 2003;14:931-937.